Morgan Stanley
ACRV icon

Morgan Stanley’s Acrivon Therapeutics ACRV Stock Holding History

Morgan Stanley’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.31K Sell
5,233
-31,438
-86% -$53.4K ﹤0.01% 7062
2026
Q1 		$51K Sell
36,671
-10,160
-22% -$17.7K ﹤0.01% 6412
2025
Q4 		$113K Sell
46,831
-10,329
-18% -$22.5K ﹤0.01% 6138
2025
Q3 		$103K Sell
57,160
-5,856
-9% -$8.23K ﹤0.01% 6135
2025
Q2 		$75K Buy
63,016
+27,795
+79% +$38.1K ﹤0.01% 6224
2025
Q1 		$71.5K Buy
35,221
+490
+1% +$2.64K ﹤0.01% 6153
2024
Q4 		$209K Sell
34,731
-1,183
-3% -$8.6K ﹤0.01% 5768
2024
Q3 		$251K Buy
35,914
+18,665
+108% +$147K ﹤0.01% 5666
2024
Q2 		$100K Buy
17,249
+6
+0% +$48 ﹤0.01% 5966
2024
Q1 		$123K Sell
17,243
-8,388
-33% -$38.9K ﹤0.01% 5910
2023
Q4 		$126K Buy
25,631
+20,688
+419% +$109K ﹤0.01% 5860
2023
Q3 		$47.3K Sell
4,943
-3,562
-42% -$41.2K ﹤0.01% 6190
2023
Q2 		$110K Buy
8,505
+2,881
+51% +$34.9K ﹤0.01% 5904
2023
Q1 		$71.4K Buy
5,624
+4,755
+547% +$79.8K ﹤0.01% 6138
2022
Q4 		$10K Buy
+869
New +$11K ﹤0.01% 6934

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley's ACRV Position: Q2 2026 in Review

Morgan Stanley reduced its Acrivon Therapeutics (ACRV) stake by 86% in Q2 2026, selling an estimated $53.4K and leaving 5,233 shares worth $9.31K. The position accounts for ﹤0.01% of the portfolio, ranked #7062.

Morgan Stanley first reported a position in ACRV in Q4 2022 and has held it in 15 quarters since. The position peaked at $251K in Q3 2024. 46 funds tracked by Wall St. Rank hold ACRV as of Q2 2026.

  • Morgan Stanley held 5,233 shares of Acrivon Therapeutics worth $9.31K as of Q2 2026.
  • Morgan Stanley sold 31,438 Acrivon Therapeutics shares in Q2 2026, an estimated $53.4K.
  • Acrivon Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #7062 holding.
  • Morgan Stanley first reported a position in Acrivon Therapeutics in Q4 2022 and has held it in 15 quarters since.
  • Morgan Stanley's Acrivon Therapeutics position peaked at $251K in Q3 2024.
  • 46 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.